NovaTarg is a research and development company founded by Dr. Ken Batchelor in 2009 for the purpose of discovering innovative medicines to treat metabolic diseases and cancer. NovaTarg’s primary focus is activation of AMPK, a key regulator of energy utilization in cells. Advanced leads have been identified and are being evaluated for drug candidate properties. NovaTarg’s first drug candidate will be for the treatment of type 2 diabetes.


First Flight Venture Center
2 Davis Drive
RTP, NC 27709

Additional Details

Arrived in RTP:
University Affiliation:
Duke University, UNC-Chapel Hill, University of Kansas

Get In Touch

(919) 406-4367
Mailing Address:
PO Box 13169
RTP, NC 27709
PR Contact:
Ken Batchelor, President and CEO
(919) 406-4367